Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119691 · ClinicalTrials.gov registry record · Phase 2
Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00119691 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 34 participants.
The verdict
NCT00119691, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
Interventions
- DRUG Nesiritide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119691
The ClinicalTrials.gov registry entry for NCT00119691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nesiritide is the first listed.
NCT00119691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119691 about?
NCT00119691 is a clinical study titled "Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction". The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
What is the current status of trial NCT00119691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2003-04. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00119691?
The interventions under investigation include: Nesiritide (DRUG).
Who is sponsoring clinical trial NCT00119691?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.